Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 8/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2982987 | 0.89 | NAMPT (0.33) | NR1H2NAMPT | |
| SCHEMBL2982986 | 0.89 | NAMPT (0.33) | NR1H2NAMPT | |
| SCHEMBL13221579 | 0.87 | NR1H2 (0.36) | NR1H2NAMPTDDB1CRBNUSP30 | |
| SCHEMBL2977167 | 0.86 | CYP3A4 (0.41) | — | |
| SCHEMBL2977165 | 0.86 | CYP3A4 (0.41) | — | |
| SCHEMBL2970151 | 0.78 | NR1H2 (0.41) | NR1H2NAMPTDDB1CRBNMAPK1 | |
| SCHEMBL8220942 | 0.78 | NAMPT (0.34) | NR1H2NAMPTDDB1CRBNMAPK1 | |
| SCHEMBL13221484 | 0.75 | SCN9A (0.36) | NR1H2NAMPTDDB1CRBN | |
| SCHEMBL8214051 | 0.75 | NR1H2 (0.40) | NR1H2NAMPTDDB1CRBNMAPK1 | |
| SCHEMBL8213557 | 0.75 | NAMPT (0.35) | NR1H2NAMPTDDB1CRBNMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781474-B2 | Inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781474-B2 | Inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100209391-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100209391-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20080019942-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080019942-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209391-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HDGF | NR1H2 323/4885NAMPT 1834/4885DDB1 715/4885 |
| US-20080019942-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, GTF3C3 | NR1H2 469/4885NAMPT 2134/4885DDB1 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.